UBS analyst Kevin Caliendo lowered the firm’s price target on GoodRx (GDRX) to $4 from $4.25 and keeps a Neutral rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
- GoodRx price target lowered to $4 from $5 at Mizuho
- Challenging Outlook for GoodRx Holdings Amid Structural and Market Pressures
- Buy Rating for GoodRx Holdings: Strategic Initiatives and Growth Prospects Amid Challenges
- GoodRx Holdings Reports Stable Q3 2025 Performance
- GoodRx Earnings Call: Growth Amid Challenges